You have asthma, and a wellness forum says VIP, vasoactive intestinal peptide, is a natural airway relaxer that can be inhaled. VIP is real: it is a nerve signal that helps relax airway muscle. But when researchers had people with asthma breathe it in, did it actually open their airways?
Not in any useful way. In a small double-blind lab study from 1984, inhaled VIP did not widen the airways of people with asthma at all, while a standard albuterol-type rescue inhaler did. VIP offered some protection against a lab trigger, but much less than the rescue medicine. A 1988 study found a similar modest effect. Neither suggests VIP can replace prescribed asthma treatment.
London, 1984: no airway opening, weaker protection
Barnes and Dixon studied six people with allergic asthma. On separate days, in random order and without knowing which was which, they inhaled VIP, a dummy solution, or salbutamol, the drug sold in the United States as albuterol.
Airway conductance, a measure of how freely air moves, did not change after VIP or the dummy solution. It rose clearly after salbutamol. The team then tested how much inhaled histamine it took to tighten each person’s airways. VIP raised that threshold a little more than twofold on average; salbutamol raised it about ninefold, a significantly bigger effect. Heart rate and blood pressure did not change. The researchers chose inhalation because VIP given into a vein has strong effects on blood vessels and the heart.
Italy, 1988: a modest shield against a drug trigger
Crimi and colleagues in Catania tested six people with asthma against propranolol, a heart drug that can tighten airways in asthma. On a first day the team measured each person’s sensitivity to propranolol. On three later days, in random double-blind order, participants inhaled ipratropium, an existing airway medicine, or VIP, or both, before repeating the challenge. VIP raised the amount of propranolol needed to narrow the airways, roughly as ipratropium did, and the two together raised it further.
What these studies cannot tell you, and what to do instead
Twelve volunteers in two lab sessions say nothing about daily control, flare-ups, emergency visits, or long-term safety. Nobody measured symptoms over weeks. The VIP used was a hospital research preparation, not the vials sold online as research-only chemicals, which are not made or tested for people to breathe or inject. Researchers have since worked on modified, longer-lasting VIP-like inhaled drugs, and none has become a standard asthma treatment.
If your asthma is not well controlled, the useful step is a visit, not a new peptide. The National Heart, Lung, and Blood Institute recommends a written asthma action plan that spells out your daily controller, your quick-relief inhaler, and the warning signs that mean you need urgent care. Keep your rescue inhaler with you, and ask whether your inhaler technique and controller choice still fit your symptoms. Not medical advice.
Sources
- Barnes PJ, Dixon CM. The effect of inhaled vasoactive intestinal peptide on bronchial reactivity to histamine in humans. Am Rev Respir Dis, 1984 (PubMed)
- Crimi N et al. Effect of vasoactive intestinal peptide (VIP) on propranolol-induced bronchoconstriction. J Allergy Clin Immunol, 1988 (PubMed)
- NHLBI: Asthma treatment and action plan
Related reading
- Inhaled VIP for lung pressure: a 20-person cath-lab study
- VIP for sarcoidosis measured immune signals, not a cure
- Why allergy shots require a clinic wait
By The Everyday Brief. AI-assisted drafting with automated source and editorial checks. Sources fetched 2026-10-22 PT. Not medical advice.